- Home
- FOLD vs PCH Comparison
FOLD vs PCH Comparison
Compare FOLD & PCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- PCH
- Stock Information
- Founded
- FOLD 2002
- PCH 1903
- Country
- FOLD United States
- PCH United States
- Employees
- FOLD N/A
- PCH N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- PCH Real Estate Investment Trusts
- Sector
- FOLD Health Care
- PCH Real Estate
- Exchange
- FOLD Nasdaq
- PCH Nasdaq
- Market Cap
- FOLD 2.8B
- PCH N/A
- IPO Year
- FOLD 2007
- PCH N/A
- Fundamental
- Price
- FOLD $9.50
- PCH $41.72
- Analyst Decision
- FOLD Strong Buy
- PCH Buy
- Analyst Count
- FOLD 8
- PCH 5
- Target Price
- FOLD $17.57
- PCH $48.50
- AVG Volume (30 Days)
- FOLD 2.4M
- PCH 401.6K
- Earning Date
- FOLD 11-06-2024
- PCH 10-28-2024
- Dividend Yield
- FOLD N/A
- PCH 4.31%
- EPS Growth
- FOLD N/A
- PCH N/A
- EPS
- FOLD N/A
- PCH 0.20
- Revenue
- FOLD $493,671,000.00
- PCH $1,058,432,000.00
- Revenue This Year
- FOLD $33.97
- PCH N/A
- Revenue Next Year
- FOLD $21.74
- PCH $1.14
- P/E Ratio
- FOLD N/A
- PCH $210.41
- Revenue Growth
- FOLD 32.58
- PCH 3.49
- 52 Week Low
- FOLD $9.02
- PCH $37.06
- 52 Week High
- FOLD $14.57
- PCH $50.04
- Technical
- Relative Strength Index (RSI)
- FOLD 28.33
- PCH 44.83
- Support Level
- FOLD $9.37
- PCH $41.13
- Resistance Level
- FOLD $9.68
- PCH $42.31
- Average True Range (ATR)
- FOLD 0.49
- PCH 0.91
- MACD
- FOLD -0.18
- PCH 0.03
- Stochastic Oscillator
- FOLD 3.96
- PCH 27.69
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.